PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4:
C07H 15/12, C12Q 1/68
C12P 21/02, C12Q 1/26
C12P 13/22, C12N 15/00, 7/00

(11) International Publication Number: WO 88/ 02372
(43) International Publication Date: 7 April 1988 (07.04.88)

(21) International Application Number: PCT/US87/02561

(22) International Filing Date: 6 October 1987 (06.10.87)

(31) Priority Application Number: 915,753

(32) Priority Date: 6 October 1986 (06.10.86)

(33) Priority Country:

(71) Applicant: DONALD GUTHRIE FOUNDATION FOR MEDICAL RESEARCH, INC. [US/US]; Guthrie Square, Sayre, PA 18840 (US).

(72) Inventor: KWON, Byoung, S.; 2501 Lynnhurst Drive, Veslect, NY 13850 (US).

(74) Agent: BARNARD, Ralph, E.; Law Offices of Ralph R. Barnard, 200 East Buffalo Street, Suite 102A, Ithaca, NY 14850 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: A cDNA CLONE FOR HUMAN TYROSINASE

(57) Abstract

The gene for human tyrosinase was cloned as a cDNA sequence prepared as a part of a lambda gt library of normal human melanocytes. The cloned gene encodes a polypeptide of 548 amino acids with a molecular weight of 62, 160 excluding a hydrophobic signal peptide.

FOR THE PURPOSES OF INFORMATION ONLY

 $Codes \ used \ to \ identify \ States \ party \ to \ the \ PCT \ on \ the \ front \ pages \ of \ pamphlets \ publishing \ international \ applications \ under \ the \ PCT.$

AΤ	Austria	FR	France	ML	Mali
ΑU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
ВJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic	SD	Sudan .
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark	MC	Моласо	US	United States of America
FI	Finland	MG	Madagascar		

WO 88/02372 PCT/US87/02561

A cDNA CLONE FOR HUMAN TYROSINASE

BACKGROUND OF THE INVENTION

Human tyrosinase is an essential enzyme which regulates the production of melanin, a group of brown or black pigments in the skin and eyes of humans. The lack of a human tyrosinase gene in usable form has greatly limited medical research in the field of albinism, and other medical and nonmedical applications relating to the control of pigment production in human melanocyte cells. This invention relates to the discovery of the cDNA gene which expresses human tyrosinase. When the cDNA is fused to an expression vector, the cDNA is useful to produce pure tyrosinase. When used as a cDNA probe the DNA is useful in the production or the control of production of human melanin. As a cDNA probe the cDNA gene is useful for genetic analysis of human albinism and melanotic and amelanotic melanoma, and also prenatal diagnosis of albinism.

There has been a minimum of research on the genetic control of melanin formation because of the lack of availability of suitable nucleic acid probe (gene sequence). cDNA for human tyrosinase is a key material for the study. The material will serve to understand why some melanoma cells lose the expression of tyrosinase gene and become more invasive. Differences in tyrosinase expression in cancer cells make it possible that the gene probe can be used in understanding and as a marker for malignancy. Understanding of the regulation of melanin biosynthesis will lead to the development of a rational chemotherapy of human melanoma because the intermediate substances of melanin are known to be toxic to pigment cells. Deletion of genes around albino locus (tyrosinase structural gene) becomes lethal in mice. The cDNA probe will open up a new research area to identify genes causing lethal effect in mouse embryo.

SUMMARY OF THE PRESENT INVENTION

The present invention resulted when a λ gt11 cDNA library of normal human melanocytes were screened with antibodies directed against purified hamster tyrosinase. Sixteen independent clones which gave a positive signal were isolated from 5×10^5 independent plaques. cDNA inserts of 13 clones among the 16 candidates cross-hybridized with each other, indicating that they were from related mRNA species. mRNA homologous to a representative cDNA > mel 34 was expressed specifically in melanocytes, detecting an approximately 2.4 kb mRNA species of human The nucleotide sequence of the three overlapping cDNA inserts spanning 1.88 kb was determined and an amino acid sequence was deduced. The human tyrosinase is composed of 548 amino acids with a molecular weight of 62,160 excluding a hydrophobic signal peptide. Mouse genomic DNA blot analysis revealed that the gene for \(\) mel 34 was deleted in albino mouse homozygous for the deletion at and around the albino locus on chromosome 7. It is concluded that λ mel 34 contained cDNA encoding human tyrosinase. Moreover, the cDNA gene for human tyrosinase was recovered from the λ mel 34 and can be used for many purposes including the production of pure human tyrosinase.

In addition, the three clones of the 11 not represented by λ mel 34 are represented by λ mel 17-1. The gene for λ mel 17-1 cDNA was not mapped at the albino locus, detected single hybridizing restriction fragment in human and mouse DNA, and was highly conserved from mouse to human. The abundance of λ mel 17-1 cRNA paralleled the melanin content in human and mouse melanocytes. The expression of λ mel 17-1 cRNA was elevated after stimulation of mouse and human melanoma cells with MSH or/and IBMX, and U-V light (such as suntan). This was also closely correlated with the elevation of melanin content. The fact that the λ mel 17-1 gene is conserved evolutionarily indicates that the molecule encoded by the λ mel 17-1 has biologiacally important functions. The expression of that gene is controlled by hormones (MSH) or U-V light and positively correlated with the melanin content. These data indicate that the gene is involved in melanin biosynthesis in addition to tyrosinase. Current studies suggest that λ mel 17-1 gene product act on melanin

biosynthesis's pathway distal to tyrosinase.

It is a primary object of the present invention to provide a new and improved cDNA gene which expresses human tyrosinase.

It is another object of the present invention to identify a new and improved cDNA gene which expresses human tyrosinase by its nucleotide sequence.

It is still another object of the present invention to teach that the cDNA from bacteriophage λ mel 34 may be used as a probe for the production or control of production of human melanin.

It is another object of the present invention to teach that the cDNA gene contained in the \(\sum_{\text{mel.34}}\) is useful as a probe for genetic analysis of human albinism and melanotic and amelanotic melanoma, and also for prenatal diagnostics for albinism.

It is another object of the present invention to teach that the cDNA gene contained in $\dot{\lambda}$ mel 17-1 is useful as a probe for detecting the change in the degree of melanization of normal human melanocytes and melanoma cells.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 in three panels depicts the isolation of human tyrosinase cDNA by antibody screening.

Figure 2 is a Northern blot analysis of poly(A)+ RNA derived from normal melanocyte, human melanotic melanoma (LC), HePG-2, HL-60, human and mouse neuroblastoma.

Figure 3 is a SDS PAGE presentation of the detection of λ mel 16 beta-galactosidase tyrosinase fusion protein.

Figure 4 is a Southern blot analysis of genomic DNA of deletion homozygous (e^{3H}/e^{3H}) in newborn mice.

Figure 5 is a Partial Restriction map and sequencing strategy for human tyrosinase cDNA.

Figures 6A, 6B, 6C and 6D together are a table showing the nucleotide sequence of cDNA encoding human tyrosinase and its deduced amino acid sequence.

- 5 -

DETAILED DESCRIPTION OF THE INVENTION

used herein the following abbreviations are used: Dopa, 3,4-dihydroxyphenylalanine; MSH, melanocyte stimulating hormone; TPA, 12-0-tetradecanoyl-phorbol-13-acetate; IBMX, isobutylmethylxanthine; TBS, M Tris HCL, pН 8.0, 0.15 NaCl; isopropyl-beta-D-thiogalactopyranoside; PMSF. phenylmethylsolfonyl fluoride; PBS, 0.01 M sodium phosphate, pH 7.4, 0.15 M NaCl; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; SSC, 0.3 M sodium chloride, 0.03 M sodium citrate; Denhardt, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin.

Described herein is the isolation of a cDNA clone for human tyrosinase. Since human tyrosinase has not been sequenced, the following properties of the cDNA lead us to conclude that the mRNA homologous to \(\lambda \) mel 34 cDNA encodes authentic human tyrosinase: 1) the protein encoded by the cDNA binds to antityrosinase antibodies; 2) the mRNA corresponding to the cDNA (cRNA) is expressed in melanocytes but not in human neuroblastoma, lymphocytes, fibroblasts or hepatoma cells; 3) the molecular weight of protein encoded by \(\lambda \) mel 34 and \(\lambda \) mel 34-related cDNA clones is in good agreement with the reported size of de novo form of human tyrosinase (Hermann, W.P. and Uhlenbruck, G. (1975) Arch. Dermatol. Res. 254, 275-280.); and 4) the mouse gene corresponding to 34 cDNA is mapped at the albino locus of the mouse chromosome 7.

The availability of tyrosinase cDNA will open up a way to investigate the cis-acting regulatory sequence responsible for melanocyte-specific gene expression and the molecular genetic basis of human albinism and the related genetic disorders such as herein discussed (Witkop, C.J., Jr. (1984) In Clinics in Dermatology Vol. 2 (1), pp 70-98, J.B. Lippincott Co., U.S.A.). There are several varieties of human albinism (Witkop, C.J. Jr., Quevodo, W., Jr. and Fitzpatrick, T.B. (1983) In the Metabolic Basis of Inherited Disease. pp 301-346 (Stanbury, J.B., Wyngarden, J.B., Fredrickson, D.S., Goldstein, J.L., Brown, M.S., eds)

McGraw-Hill, New York; King, R.A. and Witkop, C.J., Jr. (1976) Nature 263 , 69-71; King, R.A. and Witkop, C.J., Jr. (1977) Am. J. Human Genet. 29, 164-168; King, R.A., Olds, D.P., and Witkop, C.J., Jr. (1978) J. Invest, Dermatol. 71, 136-139; King, R.A. and Olds, D.P. (1981) J. Invest. Dermatol. 77, 201-204), and in some of them a normal level of hair bulb tyrosinase can be measured. It may be possible, using the cDNA probe, to determine which of the differences are related to mutations in the tyrosinase structural gene and which may be due to mutations which affect synthesis of melanosomes, packaging of enzyme into melanosomes, or degradation of the enzyme. In conjunction with the accumulated genetic information on various mouse mutants affecting coat and eye color, the cDNA probe may be used to classify the molecular genetic nature of the mutations. There are strong indications for the existence of regulatory factors encoded near the mouse albino locus which appear to control various genes that map on other chromosomes, such as liver-specific enzymes and serum proteins (Gluecksohn- Waelsch, S. (1979) 225-237; Schmid, N. Muller, G., Schutz, G. and Gluecksohn-Waelsch, S. (1985) Proc. Natl. Acad. Sci. USA 82 , 2866-2869; Loose, D.S., Schaw, P.A., Krauter, K.S., Robinson, C., Englard, S. Hanson, R.W. and Gluecksohn-Waelsch, S. (1986) Pro. Catl. Acad. Sci. USA, 83, 5184-5188). Since mel 34 detects the albino locus in mice this can be a starting material to identify such transacting regulatory genes in mice.

Posession of the cDNA probe for tyrosinase will allow further study of the regulation of tyrosinase synthesis by cAMP, MSH, and other hormones. In those cases where mRNA for tyrosinase is increased or decreased, a direct quantitation of mRNA can be made.

Tyrosinase's (EC 1.14.18.1) are copper containing enzymes that catalyze the conversion of tyrosine to dopa to dopaquinone, and thence to melanin (Mason, H.S. (1948) J. Biol. Chem. 172, 83-99). Several of the mammalian enzymes have been shown to be glycoproteins and to contain sialic acid residues (Miyazaki, K. and Ohtaki, N. (1975) Arch. Derm, Forsch. 252, 211-216; Hermann, W.P. and Uhlenbruck, G. (1975) Arch.

Dermatol. Res. 254, 275-280; Nishioka, K. (1978) Eur. J. Biochem. 85, 137-146). There are multiple sizes of tyrosinases in all mammalian species which have been studied. These may be caused by differing contents of carbohydrate and as a result of the actions of difference structural genes.

Tyrosinase is an important factor in the development of pigmentation. Oculocutaneous albinism, a group of autosomal recessive diseases in humans (Witkop, C.J., Jr. Quevedo, W., Jr. and Fitzpatrick, T.B. (1983) In the Metabolic Basis of Inherited Disease. pp 301-346 (Stanbury, J.B., Wyngarden, J.B., Fredrickson, D.S., Goldstein, J.L., Brown, M.S., eds) McGraw-Hill, New York) and animals, is characterized by reduced or no melanin in skin and eye. However, some people with the condition have as much tyrosinase activity as fully pigmented individuals (King, R.A. and Witkop, C.J., Jr. (1976) Nature 263, 69-71; King, R.A. and Witkop, C.J., Jr. (1977) Am. J. Human Genet. 29, 164-168; King, R.A., Olds, D.P., and Witkop, C.J., Jr. (1978) J. Invest. Dermatol. 71, 136-139). The albino (C) locus in mice has been mapped to chromosome 7 (Coleman, D.E. (1962) Arch. Biochem. Biophys. 69, 562-568; Gluecksohn-Waelsch, S. (1979) Cell 16, 225-237).

Studies on the regulation of tyrosinase have focused on the role of MSH in humans and in whole animals (Lerner, A.B. and McGuire, J.S. (1961) Nature 189, 176-179; Pomerantz, S.H. and Chuang, L. (1971) Endocrinol. 87, 301-310; Lee, T.H., Lee, M.S., and Lu, M.X. (1972) Endocrinol. 91. 1180-1188) and in normal and malignant melanocytes in culture (Halaban, R., Pomerantz, S.H., Marshall, S., Lambert, D.T. and Lerner, A.B. (1983) J. Cell Biol. 97, 480-488; Halaban, R., Pomerantz, S. H., Marshall, S. and Lerner, A.B. (1984) Arch. Biochem. Biophys. 230, 383-387). The later studies showed that MSH increased the rate of synthesis of tyrosinase.

A nucleic acid probe for tyrosinase would be valuable for a thorough study of the regulation of tyrosinase, the molecular genetic basis of human albinism and of various mouse mutants affecting coat and eye color, and the relationship between melanocyte differentiation and tyrosinase gene expression. Described here is the isolation of a cDNA clone for human tyrosinase which maps at or near the mouse C locus.

EXPERIMENTAL PROCEDURES

Cell culture Normal human melanocytes were cultured from newborn foreskin by a method modified by us (Halaban, R. and Alfano, F.D. (1984) In Vitro 20, 447-450) from that of Eisinger and Marko (Eisinger, M. and Marko, O. (1982) Proc. Natl. Acad. Sci. USA 79, 2018-2022). The cells were grown in Ham's F-10 medium (American Biorganics) containing 8% fetal calf serum (Gibco), 8% Nu-serum (Collaborative Research), 100 ug/ml penicillin, 200 units/mil streptomycin (Gibco), 85 nM TPA (Consolidated Midland Corp.), O.1 mM IBMX (Sigma) and 2.5 nM cholera toxin (List Biological Laboratories). In the most recent experiments cholera toxin was replaced by human placental extract (20 ug/ml) (Halaban, F. Ghosh, S., Duray, P., Kirkwood, J.M. and Lerner, A.B. (1986) J. Invest. Dermatol. 87, 95-101).

Melanoma and neuroblastoma cells were grown in Ham's F-10 medium supplemented with penicillin, streptomycin, 8% fetal calf serum and 8% Nu-serum. The melanoma cell line used was human metastatic LG (melanotic) cultured by us from the brain (Halaban, et al. supra). The human neuroblastoma SK-N-SH (Ross, R.A. and Biedler, J.L. (1985) Adv. Neuroblast. Res. pp. 249-259. (Evans, A.E., D'Ansio. G.J., Seeser, R.C., eds). Raven Press, New York) was received from Dr. J.L. Biedler, Sloan Kettering Institute, New York, NY. The murine neuroblastoma cell line NIE115 was obtained from Dr. X.O. Ereakefield, Harvard University, Cambridge, Mass.

To radiolabel proteins of normal melanocytes the cultures were first incubated for 24 hours in methionine-free medium (American Biorganics) supplemented with TPA, cholera toxin, 3% dialyzed calf serum and [35S] methionine (Amersham) (100 uCi/ml, 1390 Ci/mole). The cells

were lysed with 0.5 ml PBS containing 1% NP-40 (Sigma) and 0.1 mM PMSF (Sigma) and agitated on a vortex mixer. The lysate was centrifuged at 15,000g for 15 minutes, the specific radioactivity in protein of the supernatant was determined in 5 ul aliquots, and the supernatant was used as a crude radiolabeled tyrosinase preparation.

Preparation of cDNA libraries of normal human melanocytes Total cellular RNA of normal human melanocytes was prepared by guanidine isothiocyanate-cesiumchloride gradient centrifugation essentially as described by Chirgwin et al. (Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and Rutter, W.J. (1978) Biochemistry 18, Poly(A)+ RNA was selected by chromatography on a column of oligo d(T) cellulose (Aviv, H. and Leder, P. (1972) Proc. Natl. Acad. Sci. 69 . 1408-1412) (Collaborative Research Type 2). Double stranded cDNAs prepared from poly $(A)^+$ mRNA as previously described (Schwarzbauer, J.E., Tamkun, J.W., Lemischka, I.R. and Hynes, R.C. (1983) Cell 35, 421-431; Land, H., Grez, J., Hauser, H., Lindenmaier, W. and Schutz, G. (1981) Nucleic Acids Res. 9, 2251-2261). The cDNA was EcoRI-methylated at internal EcoRI restriction sites with EcoRI methylase (New England Biolabs) (Maniatis, T., Hardison, R.C., Lacy, E., Lauer, J., O'Connel, C., Quon, D., Sim, G.K. and Efstratiadis, A. (1978) Cell, 687-701) to prevent degradation at the step of EcoRI-linker addition. EcoRI linkers were ligated to both ends of cDNA molecules which were blunt-ended by treating with S1 nuclease followed by E. coli DNA polymerase 1 large fragments. The cDNAs were fractionated on 1 ml columns of Bio-gel A-150m (Bio Rad) and enriched for those composed of over 400 base pairs. λ gt11 DNA (Young, R.A., and Davis, R.W. (1983) Proc. Natl. Acad. Sci. USA 80 , 1194-1198) was digested with EcoRI and treated with bacterial alkaline phosphatase (Worthington, 0.2u/ug DNA) at 65° for 1 hour to decrease self-ligation. The cDNAs were inserted into the unique EcoRI site of λ gt11 cloning vector. The recombinant phage DNA was packaged in vitro as described by Grosveld et al (Grosveld, F.G., Dahl, H.H.M., deBoer, E. and Flavell, R.A. (1981) Gene 13, 227-237). The λ gt11 library contained 1.7 x 106 independent plaques. A pilot experiment showed that 88% of the plaques

contained cDNA inserts based on beta-galactosidase activity. The λ_{gt11} cDNA library was amplified in <u>E. coli</u> strain Y1088 (Huynh, T.V., Young, R.A. and Davis, R.W. (1984) In DNA CLoning: A Practical Approach, vol. 1, pp. 49078 (D. Glover, ed.) IRL Press, Arlington, VA) as a host and stored at 4°C.

Screening for the gene products of the \(\lambda \) gt11 melanocyte cDNA library with antityrosinase antibodies The immunobiological screening was carried out as described by Young and Davis (Young, R.A. et al. supra). Recombinant phages were absorbed to bacterial strain Y1090 and plated on 150 mm L-agar plates. The plates were incubated at 42°C for 3 hours. Nitrocellulose filters, soaked in 50 mM IPTG were placed on the plates and incubated for 3 hours at 37°C. The filters were removed and washed in TBS twice and treated with 20% fetal calf serum in TBS for one hour. The filters were washed with TBS twice and TBS + 0.1% NP-40 cnce. The filters were incubated with antityrosinase antibodies (available from Dr. Seymour H. Pomerantz, Department of Biological Chemistry, University of Maryland School of Medicine, Baltimore, Maryland 21201) in TBS plus 20% fetal calf serum in a sealed plastic bag overnight at 4°C. At the same time another set of IPTG-treated filters were overlayed on plaques and incubated overnight at 37°C to obtain duplicate filters. The second set of filters were processed the same way as the first set of filters except that the binding period to antityrosinase antibody was two hours at room temperature. Both sets of filters were washed extensively with TBS and TBS plus 0.1% NP-40 at room temperature. [1251] protein A (New England Nuclear) was diluted to 1 x 105 cpm/ml in TBS and incubated with the filters for 1 hour at room terperature with shaking. Filters were washed three times with TBS and blotted dry and autoradiographed with intensifying screen at -70°C. The duplicate filters were compared to search for positive signals in both filters.

Detection of fusion protein The lysogens of the recombinant and nonrecombinant λ gt11 were prepared employing E. coli strain Y1089 (Huynh, T.V., Young, R.A. and Davis, R.W. (1984) In DNA Cloning: A Practical Approach, vol. 1, pp. 49-78 (D. Glover, ed.) IRL Press,

Arlington, VA). The lysogens were grown at 32°C until they reached logarithmic phase (OD600 = 0.5). Lytic replication was then induced by a temperature shift (42°C, 20 min) and cultures were incubated at 37° for 3 hours in the presence of IPTG at a final concentration of 1 mM. The bacterial cells were suspended in a buffer containing 10 mM Tris HCL pH 7.4, 0.15 M NaCl, 1 mM PMSF, 50 ug/ml DNase 1 (Sigma) and 50 ug/ml of RHase (Boehringer Mannheim). The soluble fractions of the sonicated bacterial cell suspension were run on a 6% polyacrylamide gel (Laemmli, U.K. (1970) Nature 227, 680-685).

Immunoprecipitation and competition with antityrosinase antibodies For competition experiments, antityrosinase antibodies were incubated on ice overnight with bacterial lysates prepared from E. coli Y1089 lysogens of λ gt11 or λ gt11 plus cDNA. [358] methionine labeled extract from black foreskin melanocytes (6 x 106 cpm in protein/assay) was added to each assay tube, followed 15 minutes later by 10 ul of IgGSorb (The Enzyme Center, Inc., 250 mg/ml). At the end of 15 minutes incubation with IgGSorb, the cell lysates were centrifuged at 13,000g for 0.5 minutes, the pellet of IgGSorb with bound immune complexes washed 3 times with PBS plus 0.1% NP-40 and once with PBS. The immune complexes were eluted from the IgGSorb with sample buffer (Laemmli supra) and subjected to polyacrylamide gel electrophoresis followed by fluorography of the gels as described before (Halaban et al. supra). For quantitation of labeled protein, gel slices were taken from relevant radioactive bands, rehydrated with 25 ul water and digested overnight with 5% Protosol (National Diagnostics) in Econofluor (NEN) at 37°C, and the radioactivity counted.

Northern blot analysis Poly(A)+ RNA from normal human melanocytes, melanoma cells, neuroblastoma cell lines, HL-60 (human promyelocytic leukemia cell line) and HepG-2 (human hepatocarcinoma cell line) was fractionated on a 1.2% formaldehyde denaturing gel (Thomas, P.S. (1980) Proc. Natl. Acad. Sci. USA 77, 5201-52005) and transferred to a nitrocellulose filter or Gene Screen plus membrane (NEN). [32P] labeled cDNA probes were hybridized overnight to the filter at 42°C in 5

times concentrated SSC, 50% formaldehyde, 50 mM sodium phosphate buffer pH 6.8, 10% dextran sulfate, Denhardt, 0.1% SDS and 250 ug/ml denatured salmon sperm DNA. Filters were then washed three times for 5 minutes each in 2 times concentrated SSC and 0.1% SDS at room temperature and three times at 42°C in 5 times concentrated SSC, 5% formaldehyde, 50 mM sodium phosphate buffer pH 6.8, 10% dextran sulfate, Denhardt, 0.1% SDS and 250 ug/ml denatured salmon sperm DNA. Filters were then washed three times for 5 minutes each in 2 times concentrated SSC and 0.1% SDS at room temperature and three times at 42°C in 0.1 concentrated SSC and 0.1% SDS. The filters were autoradiographed at -70°C. When a Northern blot of Gene Screen plus was used multiple times for hybridization, the previous probe was removed by treating the membrane in 10 mM Tris-HCl pH 7.0 and 0.2% SDS at 85°C for 1 hour.

Genomic Southern blot analysis High molecular weight DNAs of murine embryos homozygous for the lethal deletion c3H/c3H, heterozygous for the deletion, (c^{3H}/c^{ch}) and of normal homozygote chinchilla (cch/cch), were prepared as described previously (Grass-Bellard, M., Oudet, P. and Chambon, P. (1973) Eur. J. Biochem. 36 , 32-38). c^{3H}/c^{3H} and c^{3H}/c^{ch} mice were obtained from Dr. Gluecksohn-Waelsch at the Albert Einstein College of Medicine and may be purchased from Johnson Laboratories, Inc., Bar Harbor, Maine. Restriction endonuclease digests of DNA were electrophoresed in a 0.8% agarose gel at 4°C. The gel was denatured with 0.5 M NaCH/1 M NaCl and neutralized with 1 M Tris HCl pH 8.0/1 M NaCl. The DNA in the gel was transferred to Gene Screen plus as described by Southern (Southern, E. (1975) J. Mol. Biol. 98, 503-517). For a low stringent hybridization and washing the blot was hybridized with the [32P] labeled cDNA in 6 times concentrated SSC, 5 times concentrated Denhardt solution, 0.5% SDS and 100 ug/ml denatured salmon sperm DNA for 24 hours at 58°C. The filters were then washed two times at room temperature for 10 minutes each in 2 times concentrated SSC, 0.1% SDS and two times at 55°C for 30 minutes each in 2 times concentrated SSC and 0.1% SDS, and two times at room temperature for 30 minutes in SSC.

Isolation of hage DNA and preparation of inserted DNA Recombinant phage DNA was prepared as described by Davis et al (Davis, R.W., Botstein, D. and Roth, J.R. (1980) Advanced Bacterial Genetics, pp. 106-107, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). The recombinant DNA was cut with EcoRI, and the cDNA inserts were separated from hage arms by 1% agarose gel. The cDNA bands were cut out of the agarose gels, run on 5% polyacrylamide gels, eluted from the gels in 0.1 SSC, and precipitated with ethanol.

<u>DNA sequencing</u> DNA restriction fragments, subcloned in M13 vectors (Messing, J., Crea, R. and Seeburg, P.H. (1981) Nucleic Acids Res. 9. 309-322), were sequenced by the dideoxy chain termination technique (Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. Acad. Sci. USA 74, 5463-5467), with modifications made to accommodate 2'-deoxy-adenosine 5'-[alpha-[358]thio] triphosphate (Biggin, M., Gibson, T. and Hung, G. (1983) Proc. Natl. Acad. Sci. USA 80, 3963-3965).

RESULTS

Isolation of cDNA clones from human melanocyte > gt11 library which react with antityrosinase antibodies A > gt11 cDNA library of normal human melanocytes was screened with rabbit antityrosinase antibodies raised against purified hamster tyrosinase. The antityrosinase antibodies have been shown to cross react with human, murine and avian tyrosinase (Halaban, R. et al. (1983) supra; Halaban, R. et al. (1984) supra). The antibodies immunoprecipitated newly-synthesized as well as processed tyrosinase and were abosrbed completely by extracts from melanocytes but not from fibroblasts.

Initial screening of approximately 500,000 recombinant phages with rabbit antityrosinase antibodies identified sixteen independent clones which gave positive signals. These clones were consistently reactive with antityrosinase antibodies but not with nonimmune rabbit serum during

several rounds of screening for plaque-purification. Figure 1 shows an example of duplicate primary (a and b) and the third round (c) of screening. Figure 1 depicts the isolation of human tyrosinase cDNA by antibody screening. A gt11 cDNA library of human melanocytes was screened with antityrosinase antibody directed against hamster tyrosinase and 1251-labeled protein A (NEN). Filter panels a and b represent duplicate filters prepared from the same plate of mgt11 cDNA library. Signals in filter a (1, 2 and 3) correspond to those in filter b. It was found that the duplicate screening method was helpful in discriminating false-positive signals. Filter panel c shows the third round of screening during the plaque purification of mel 34.

Recombinant phage DNAs from each of the 16 clones were prepared, digested with EcoRI to excise the cDNA insert and fractionated on a 1% agarose gel. Sizes of the cDNA inserts varied from 0.2 to 1.6 kb. The longest cDNA insert (§1.6) kb) from mel 34 was hybridized to 12 other cDNA inserts and shared an overlapping restriction pattern. The other three cDNA inserts were not related to the thirteen cDNA clones. The thirteen cDNA inserts were partially overlapping but none of them were the same clone. The fact that overlapping sequences were found repeatedly indicates that the antibody reacted to the peptides encoded by specific sequences present in the cDNA species. The 1.6 kb cDNA insert of mel 34 was subcloned into PBR322 to yield pmel 34 and used to amplify the cDNA insert.

mRNA homologous to λ mel 34 is expressed preferentially in melanocytes Tyrosinase is presumed to be expressed only in pigment cells. To examine whether λ mel 34 homologous mRNA is expressed only in melanocytes, Northern blot analysis of poly(A)+ mRNA from normal human melanocytes, human melanotic melanoma cells (LG), human neuroblastoma, murine neuroblastoma, HePG-2 (human hepatoma cell line) and HL-60 (human promyelocytic leukemia cell line) was performed using [32P] labeled λ mel 34 cDNA as a probe. Figure 2 is a Northern blot analysis of poly (A)+ RNA (a) of normal human melanocyte (lane 1), LG (lane 2), HepG-2 (lane 3) and HL-60 (lane 4) cells, and 10 ug of

poly(A) + RNA (b) of normal human melanocyte (lane 5), LG (lane 6), human neuroblastoma (lane 7) and mouse neuroblastoma cells (lane 8) were fractionated on 1.2% formaldehyde denaturing agarose gel, blotted and hybridized with $[^{32}P]$ - labeled \bigwedge mel 34 cDNA (upper arrow). The same filter was used to hybridize to [32]-labeled mel 14-2 (bottom arrow) to show that each lane contained RNA as indicated above and the RNA was relatively intact. Mel 14-2 is a cDNA clone which was isolated from human melanocyte cDNA library and has been used as a control probe because the corresponding RNA was detectable in similar amounts from all human and mouse cells tested. As shown in Figures 2a and b, \(\) mel 34 hybridized to 21S (\(\) 2.4 kb) mRNA species of normal human melanocytes and human melanotic melanoma cells but not to HePG-2, HL-60, human or murine neuroblastoma mRNA. A cDNA fragment (λ mel 14-2) is isolated from melanocyte cDNA library was used as a control probe to show that a similar amount of mRNA was loaded in each lane (Fig. 2a and b). In addition, mel 34 cRNA was not expressed in other human and mouse fibroblasts and lymphocytes (data not shown). Further studies showed that \(\structure \text{mel 34 cRNA} \) expression was correlated with tyrosinase activity and melanin content in human melanoma cells. Amelanotic melanoma cells (no or little melanin-containing cells) expressed far less > mel 34 cRNA than normal or melanotic melanoma cells.

Fusion protein of \(\) mel 34-related clone, \(\) mel 16 To characterize the fusion protein further, lysogens of \(\) gt11 and \(\) mel 16 (§C.7 kb), which were isolated at an earlier stage of this work and which cross hybridized to \(\) mel 34, were prepared and analyzed by 6% SDS PAGE and competitive immunoprecipitation assay. Figure 3 depicts the detection of \(\) mel 16 beta-galactosidase-tyrosinase fusion protein. Panel a: Bacterial lysates were prepared from the lysogens Y1089/\(\) gt11 (lanes 1 and 2), Y1089/\(\) mel 19 (lane 3) and Y1089/\(\) mel 16 (lanes 4 and 5) following inactivation of the temperature-sensitive repressor at 42°C and subsequent incubation in the absence (lanes 1 and 5) or presence (lanes 2, 3, and 4) of IPTG. \(\) mel 16 and \(\) mel 19 were \(\) mel 34-related clones which were isolated in the early phase of this work. Reduced samples were run on a 6% SDS-polyacrylamide gel, and staired with

Coomassi-blue. The IPTG-dependent production of beta-galactosidase (lane 2) and \sim 140 kd \nearrow mel 16 fusion protein (lane 5, arrow) was noted. Protein sizes in kilodaltons are marked left. Panel b: The lysate of mel 16 or gt11 lysogen was used to compete with metabolically labeled human melanocyte cell extract for antityrosinase antibodies. Constant amounts of lysates of gt11 or mel 16 lysogens ($\sim 2 \times 10^7$ cells in 100 ul volume) were incubated with 5 ul of 1:100 dilute of antityrosinase antibodies. The absorbed antibodies were used to immunoprecipitate the [35S] labeled human melanocyte extract (6 x 106 protein/tube). The eluted immune complexes were analyzed on an 8.5% polyacrylamide gel. There were 3,780 cpm in control lane and 1,186 cpm in λ mel 16 lane, in the gel slices taken from the tyrosinase bands (arrow). As shown in Figure 3a, a fusion protein was produced in Y1089 (λ mel 16) which had a relative size of approximately 140,000 daltons. This was approximately 25,000 daltons larger than that of E. coli beta-galactosidase. This indicates that the cDNA in λ mel 16 is fused to beta-galactosidase gene in frame, producing an almost entire protein encoded by the cDNA. Synthesis of both beta-galactosidase and the fusion protein was dependent on induction with IPTG. The lysate of λ mel 16 lysogen was used to compete with metabolically labeled melanocyte cell extract for antityrosinase antibodies. A typical experiment is shown in Figure 3B. When bacterial lysates of λ gt11 or λ mel 16 lysogens (approximately 2 x 10^7 cells in 100 ul volume) were incubated with 1 ul of 1:100 dilution of antityrosinase antibodies, approximately 70% of antityrosinase activity was absorbed by λ mel 16 lysate compared with λ gt11 control lysates 'based upon the intensity of tyrosinase bands and radioactivity count of the gel slices taken from tyrosinase bands: Since the antibody preparation is poly-clonal the λ mel 16 encoding protein, containing only a partial sequence of tyrosinase, may not bind all of the antityrosinase antibodies.

Gene for λ mel 34 is deleted in chromosome of albino locus-deleted mouse, c3H/c3H Earlier studies showed that the skin of mice carrying the albino locus deleted mutant c3H/c3H has no tyrosinase activity (Gluecksohn-Waelsch, S. (1979) supra). However, the

tyrosinase activity levels in the skin of mice heterozygous to lethal albino deletions and chinchilla (c^{3H}/c^{ch}) were shown to be intermediate between normal (c^{ch}/c^{ch}) and mutant (c^{3H}/c^{3H}) homozygotes, confirming that the albino locus of mice encodes the structural gene of tyrosinase.

Because the deletion around the albino locus in $c^{3H/c^{3H}}$ mice is large enough to cover the tyrosinase gene (Gluecksolh-Waelsch, S. (1979) supra), authentic tyrosinase cDNA should not detect any band $(c^{3H/c^{3H}})$ mice DNA but should detect hybridizing bands of half normal intensity of the homozygote (c^{ch}/c^{ch}) in the heterozygous litter mate $(c^{3H/c^{ch}})$. To test this prediction, genomic DNAs from $(c^{3H/c^{3H}})$, $(c^{3H/c^{ch}})$ and (c^{ch}/c^{ch}) were digested with EcoRI and the fragments were separated on 0.8% agarose gel, transferred to Gene Screen Plus, and probed with the $[^{32}]P$ -labeled \nearrow mel 34 cDNA. After autoradiograph, the \nearrow mel 34 cDNA probe was stripped and the same filter was probed with $[^{32}]P$ -labeled \nearrow mel 17-1 cDNA. \nearrow mel 17-1 is one of the three cDNA clones among the initial 16 clones which is unrelated to \nearrow mel 34.

As shown in Figure 4a, λ mel 34 detected three hybridizing fragments whose sizes were approximately 4.5 kb, 12.0 kb and 14.5 (cch/cch) DNA. According to the hybridization conditions the mouse tyrosinase gene. Those three bands were also detected in (c3H/cch) at approximately half the intensity of that with (cch/cch) DNA. No hybridizing fragment was detected in (c3H/c3H) DNA even after longer exposure. Therefore, the mouse genes whose sequences are homologous to cDNA contained in A mel 34 are located at or near the albino locus. Figure 4 is a Southern blot analysis of genomic DNA of deletion homozygous (c^{3H}/c^{3H}) (lane 1), (c^{3H}/c^{ch}) (lane 2) and (c^{ch}/c^{ch}) (lane 3) mice was digested with EcoRI, run on a 0.8% agarose gel, transferred to Gene Screen Plus and hybridized to λ mel 34 cDNA (a). The same filter was probed with mel 17-1 after stripping \(\) mel 34 cDNA probe (b). \(\) mel 17-1 is one of the sixteen clones which we initially isolated and proved

not to be related to mel 34. Size markers are Hind III fragments of phage DNA. As shown in Figure 4b, mel 17-1, one of the three other clones we initially isolated, detected a 13.0 kb band in all three mouse DNAs at relatively similar intensities. Therefore mel 17-1 clone is unrelated to the albino locus.

Nucleotide sequence analysis The entire nucleotide sequence of three overlapping cDNA clones (λ mel 34, λ mel 16 and mel 40) was determined according to the strategy shown in Figure 5. Figure 5 shows partial restriction map and sequencing strategy for human tyrosinase cDNA. The protein-coding region is indicated by an open box and a putative signal peptide is represented by a shaded box. Horizontal arrows under the 3 inserts show the direction and extent of sequencing used to generate the sequence presented in Figure 6. Restriction sites used for sequencing are indicated. The scale at the top indicates the nucleotide number. The 5' sides of the other 10 clones were also sequenced. The nucleotide sequence of tyrosinase cDNA revealed a single long open reading frame, beginning with the first nucleotide after the EcoRI linker. This open reading frame is in frame with the lacZ gene of the λ gt11 vector. We found that the other 10 clones are also fused in frame with lacZ gene. This property was helpful in assigning the open reading frame even though the cDNAs did not start the first ATG codon. This reading frame codes for a polypeptide of 560 amino acids with a molecular weight of 63,549 (Figure 6). Figure 6 lists nucleotide sequence of cDNA encoding human tyrosinase and its deduced amino acid sequence. The nucleotide sequence of message strand is numbered in the 5' to 3' direction. Numbers above each line refer to nucleotide position. Nucleotide residue 1 is the T of the first codon TTC of putative mature protein, and the nucleotides of a portion of putative signal peptide are indicated by negative numbers. The predicted amino acid sequence is shown below the nucleotide sequence. Numbers below the amino acid sequence refer to amino acid position, beginning with the amino-terminal residue of the mature tyrosinase. The preceding residues of a portion of putative signal peptide are indicated by negative numbers. Potential glycosylation signals and potential polyadenylation signals are

underlined. - - - indicates stop codon. The codon specifying carboxy-terminal leucine is followed by the translation termination codon TAA (Nucleotide residue, 1645-1647). No nucleotide differences were observed among the three cDNA clones except that they differ in length. The 3'-untranslated sequence determined from \(\simeting \text{mel 34, } \simeting \text{mel 16 and } \) mel 40 does not extend as far as the poly(A)+ tail. However \(\simeting \text{mel} \) mel 40 contains a potential polyadenylation signal of ATTAAA (Goeddel, D.V., Leung, D.W., Dull, T.J., Gross, M., Lawn, R.M., McCandliss, R., Seeburg, P.H., Ullrich, A., Yelverton, E. and Gray, P.W. (1981) Nature 290, 20-26) (nucleotide residues, 1822-1827).

Amino acid sequence The sequence of the first eleven amino acid residues exhibits a feature characteristic of the signal peptide of secretary and membrane-associated proteins (Blobel, G. and Dobberstein, B. (1975) J. Cell Biol. 67, 852-862), which mainly contains hydrophobic amino acide (9 out of 11) and terminate with serine having a small side chain (Steiner, D.F., Quinn, P.S., Chan, S.J., Marsh, J. and Tager, H.S. (1980) Ann. N.Y. Acad. Sci. 343 , 1-16) (Figure 6). Therefore, a possible site for cleavage of the signal peptide of putative tyrosinase precursor is after the serine residue at position 1 of phenylalanine (Figure 6). This prepeptide is probably involved in the transfer of tyrosinase into the melanosome. Thus, mature tyrosinase is composed of 548 amino acids with a molecular weight of 62,160. As tyrosinase is a glycoprotein, we exammined the possible N-glycosylation sites. There are five potential aspargine-linked glycosylation signals, Asn-X-Ser-S or Thr, where X is any amino acid except proline (Marshall, R.D. (1974) Biochem. Soc. Symp. 40, 17-26; Bause, E. (1983) Biochem. J. 209, 331-336). The possible glycosylation sites are the asparagine residues at positions 73, 98, 148, 217 and 324 as underlined in Figure 6. Tyrosinases contain two copper atoms per enzyme molecule (Nishioka, K. (1978) Eur. J. Biochem. <u>85</u>, 136-146; Lerch, K. (1976) FEBS Letters <u>69</u> , 157-160). Therefore, we examined the possible copper-binding sites by comparison with human (Jabusch, J.R., Farb, D.L., Kerschensteiner, D.A. and Deutsch, H.F. (1980) Biochemistry 19, 2310-2316) and bovine (Richardson, J.S., Thomas, K.A., Rubin, B.H. and Richardson, D.C.

(1975) Proc. USA <u>72</u> , 1349-1353) superoxide Natl. Acad. Sci. dismutase. Crystallographic study of bovine superoxide dismutase (Richardson, J.S. et al. (1975) supra) has shown that His-44, His-46, and His-61 are ligands to copper. There are 15 histidine residues in the deduced amino acid sequence of human tyrosinase. Histidine residues at positions 350, 354, 360 and 377 showed a similar arrangement to bovine superoxide dismutase. By analyzing albino and normal human DNA using λ mel 34 as a probe the genetic defect of tyrosinase gene in human albinism will be established. The cDNA contained in λ mel 34 will be further used to analyze amniotic cell DNA of suspected individuals for prenatal diagnosis of albinism. The cDNA (λ mel 34) will be used to produce a pure human tyrosinase by recombinant DNA technology in bacteria. This will facilitate obtaining a large quantity of pure human tyrosinase. Obtaining a large quantity of pure human tyrosinase is essential to study of the three dimensional structure of the enzyme. Clarification of the tyrosinase structure will lead to establishment of the rationale for chemotherapy against malignant melanoma because presursors to melanin is toxic to melanotic melanoma cells.

To produce the tyrosinase in $\underline{E.~coli}$, λ mel 34 cDNA will be fused to an expression vector (Tac) which has \underline{T} rp and $\underline{1}$ ac promoter together. Tac, the expression vector is available communally through suppliers such as U.S. Pharmacia, Inc. The construct will be expressed in $\underline{E.~coli}$ strain MM294. Subsequently the tyrosinase will be purified by affinity column chromatography.

Subsequently it was found that the cDNA inserts of the three clones which were not related to λ mel 34 were cross-hybridized to each other and expressed specifically in melanocytes. This indicates that they were not isolated spuriously, rather that the protein encoded by the cDNAs were reactive to the antityrosinase antibody and had melanocyto-specific functions.

The representative clone λ mel 17-1 detected approximately 2.5 kb mRNA species in only melanocytes. The gene for > mel 17-1 cDNA was not mapped at the albino locus, detected single hybridizing restriction fragment in human and mouse DNA, and was highly conserved from mouse to human. The abundance of λ mel 17-1 cRNA paralleled the melanin content in human and mouse melanocytes. The expression of λ mel 17-1 cRNA was elevated after stimulation of mouse and human melanoma cells with MSH or/and IBMX, and U-V light (such as suntan). This was also closely correlated with the elevation of melanin content. The fact that the mel 17-1 gene is conserved evolutionarily indicates that the molecule encoded by the λ mel 17-1 has biologically important functions. The expression of the gene is controlled by hormones (MSH) or U-V light and positively correlated with the melanin content. These data indicate that the gene is involved in melanin biosynthesis in addition to tyrosinase. Current studies suggest that ' > mel 17-1 gene product act on melanin biosynthesis's pathway distal to tyrosinase.

The foregoing description has been directed to particular embodiments of the invention in accordance with the requirements of the Patent Statutes for the purposes of illustration and explanation. It will be apparant, however, to those skilled in this art that many modifications and changes will be possible without department from the scope and spirit of the invention. It is intended that the following claims be interpreted to embrace all such modifications.


Bacteriophage λ mel 34 cDNA has been deposited at the American Type Culture Collection under ATC No. 40265 and will be available after this Patent Application issues.

Bacteriophage λ mel-17-1 cDNA has been deposited at the American Type Culture Collection under ATC No. 40264 and will be available after this Patent Application issues.

I claim:

- 1. A cDNA gene for human tyrosinase.
- 2. A cDNA gene for human tyrosinase comprising a nucleotide sequence as shown in Figures 6A, 6B, 6C and 6D.
- 3. A bacteriophage vector for use in cloning human tyrosinase cDNA comprising a replicon identified as λ mel 34 cDNA deposited at the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Maryland 20852 under ATC No. 40265.
 - 4. A method of making human tyrosinase comprising the steps of:
 - a. fusing λ mel 34 cDNA to an expression vector (Tac);
 - b. express tyrosinase in E. coli;
 - c. purify the resulting tyrosinase.
- 5. A cDNA gene for human tyrosinase comprising the cDNA recovered from the λ mel 34 cDNA as deposited at the A.T.C. Collection under No. 40265.
- 6. The method of using the cDNA gene recovered from the λ mel 34 cDNA as deposited at the A.T.C. Collection under No. 40265 as a probe for genetic analysis of human albinism.
- 7. The method of using the cDNA gene recovered from the λ mel 34 cDNA as deposited at the A.T.C. Collection under No. 40265 as a probe for melanotic and/or amelanotic melanoma.
- 8. The method of using the cDNA gene recovered from the λ mel 34 cDNA as deposited at the A.T.C. Collection under No. 40265 as a probe for the diagnostics of prenatal albinism.

- 9. The method of using the cDNA gene recovered from the λ mel 34 cDNA as deposited at the A.T.C. Collection under No. 40265 for the production or regulation of the production of human melanin.
- 10. A bacteriophage vector for use as a probe for melanin biosynthesis comprising a replicon identified as > mel 17-1 cDNA and on deposit at the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Maryland 20852 under ATC No. 40264.
- 11. The cDNA gene comprising the cDNA recovered from the \$\times 17-1 cDNA\$ as deposited at the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Maryland 20852 under ATC No. 40264.
- 12. The method of using the cDNA gene recovered from the \$\times \text{mel 17-1}\$ cDNA as deposited at the American Type Culture Collection under ATC No. 40264 to detect the change in the degree of melanization of human melanocytes.







FIG. 2








FIG. 4 SUBSTITUTE SHEET





										••									
-4	0			-30			-20)		. - !	10		-1	1			10		
GAA Eco		CTG Leu	CTC	CTC	u Al	r GT	TT(TAC L Ty	C TG(CTC	CTO	G TG(G AGT P Set -1	TTO Pho	C CA • G1	G AC	C TC	C GC	r GGC a Gly
20	ı		3	30			40			;	50		6	50			70		
CAT His	Phe	Pro	AGA Arg	YT	C TG	f GT(C TC	C TC	r And	S AAG	C CTO	G ATO	G GAC E Glu 20	Ly	G GA B G1	A TG	C TG	CC.	A CCG o Pro
80			9	0			100	-		110)		12	20			130		
TGG Trp	AGC Ser	GGG	Thr 30		A GTO y Vai	Cyt	GG Gl	CAC Gli	CT1	TC/ Sei	CGC Gly	C AG	A GGT B Gly 40	Se:	C TG	T CAC	G AA1 B Ac i	r ate	CTT Leu
140	:		15	0			160			170)		18	10			190		
CTG Leu	TCC Ser	AAT	GCA Ala 50	FEC	CTT Leu	GG Gly	Pro	CAA Glr	TTT Phe	CCC Pro	TTC Phe	C ACA	GGG Gly 60	Val	GA1	C GAC	CGC Arg	GAC Glu	TCG Set
200			21	0.,			220	•		230)		24	0			250		
TGG Trp	CCT Pro	TCC Ser	GTC Val 70	TTT Phe	TAT	AAT Asn	AGG	ACC	TGC Cys	CAG Gln	TGC Cys	TCT Ser	GGC Gly 80	Asn	TTC Phe	ATG Met	GGA Gly	TTC Phe	AAC
260			270	0			280			290			30	0			310		
TGT Cys	GGA Gly	AAC A an	TGC Cys 90	AAG Lys	TTT	GGC Gly	TTT Phe	TGG Trp	GGA Gly	CCA Pro	AAC Asn	TGC Cys	ACA Thr 100	GAG Glu	AGA Arg	CGA Arg	CTC Leu	TTG Leu	GTG Val
320			330)		•	340			350			360)		:	370		
AGA .	AGA Arg	Asn	ATC Ile 110	TTC Phe	GAT Asp	TTG Lau	AGT Ser	GCC Ala	CCA Pro	GAG Glu	AAG Lys	GAC Asp	AAA Lys 120	TTT Phe	TTT Phe	GCC Ala	TAC Tyr	CTC Leu	ACT Thr
380			390	i		4	00			410	-		420)		4	430		
TTA (Leu /	GCA /	Lya I	CAT . H1# 1	ACC Thr	ATC Ile	AGC Ser	TCA Ser	GAC Asp	TAT Tyr	GTC Val	ATC Ile	CCC Pro	ATA Ile 140	GGG Gly	ACC Thr	TAT Tyr	GGC Gly	CAA Gln	ATG Met
440			450			4	60			470			480			4	90		
AAA A Lys <u>A</u>		ily S																	

FIG. 6A

SUBSTITUTE SHEET

500	510	520	. 530	540	550
CAT TAT T	AT GTG TCA ATG yr Vel Ser Het 170	GAT GCA CTG Asp Als Leu	CTT GGG GGA Leu Gly Gly	TAT GAA ATC TGG Tyr Glu Ile Tr	G AGA GAC ATT GAT Arg Asp Ile Asi
560	570	580	590	600	· 610
TTT GCC C. Phe Ala H:	AT GAA GCA CCA Le Glu Ala Pto 190	GCT TTT CTG Ala Phe Leu	CCT TGG CAT Pro Trp His	AGA CTC TTC TTC Arg Leu Phe Leu 200	TTG CGG TGG GAA
620	630	640	650	660	670
GAA GAA AT Glm Glu II	C CAG AAG CTG Le Gin Lys Leu 210	ACA GGA GAT	GAA AAC TTC .	ACT ATT CCA TATE The Ile Pro Tyr 220	TGG GAC TGG CGG
680	690	700	710 .	. 720	730
GAT GCA GA Asp Ala Gl	A AAG TGT GAC u Lys Cys Asp 230	ATT TGC ACA (GAT GAG TAC A	ATG GGA GGT CAG Met Gly Gly Gln 240	CAC CCC ACA AAT His Pro Thr Asn
740	750	760	770	780	790
CCT AAC TT. Pro Asn Les	A CTC AGC CCA (u Leu Ser Pro (250	GCA TCA TTC T Ala Ser Phe P	TC TCC TCT T he Ser Ser T	GG CAG ATT GTC rp Gln Ile Val 260	TGT AGC CGA TTG Cys Ser Arg Lau
800	810	820	830	840	850
GAG GAG TAC Glu Glu Tyr	AAC AGC CAT C Asn Ser His G 270	AG TCT TTA TO	GC AAT GGA AG	CG CCC GAG GGA hr Pro Glu Gly 280	CCT TTA CGG CGT Pro Leu Arg Arg
860	870	880	890	900	910
AAT CCT GGA Asn Pro Gly	AAC CAT GAC A Aan His Asp L 290	AA TCC ACA AC ys Ser Thr Th	C CCA AGG CT r Pro Arg Le	CC CCC TCT TCA (ou Pro Ser Ser)	GCT GAT GTA GAA
920	930	940	950	960	970
TTT TGC CTG Phe Cys Leu	AGT TTG ACC CA Ser Leu Thr GJ 310	A TAT GAA TC .n Tyr Glu Se	T GGT TCC AT r Gly Ser Me	G GAT AAA GCT G t Asp Lys Ala A 320	CC AAT TTC AGC
980	990	1000	1010	1020	1030
LUG VLE VAU	ACA CTG GAA GG Thr Lau Glu Gl 330	A TTT GCT AGT y Phe Ala Ser	CCA CTT ACT	GGG ATA GCG GG GG GIJ Ile Ala A	AT GCC TCT CAA sp Ala Ser Gln

FIG 6B

SUBSTITUTE SHEET

1040	}		105	0		1	060		•	1070)	•	108	0		1	090		
				i Ası										Va)					TCT Ser
1100):		111	0		1	120			1130)		114	0		1	150		
GCC Ala	AA	C GAS	CG1 PARI 170	, H	TTO Pho	CTI Lev	CTC Leu	ACC Thr	ATG He c	CAT	Lau	TTO	ACA Thr 380	Val	Pho	TTG Lou	AGO AT	CAG Glm	TGG TTP
1160	ı		117	0		1	180			1190).	-	120	0		٠ 1	210		
CTC Lau	G1:	L AGG	G CAC B H14 390	Ari	r cci	CTI Leu	CAA Glm	GAA Glu	GTT Val	TAT	CCA Pro	GA/	GCC 400	Ast	GC.	CCC Pro	ATT Ila	GGA Gly	CAT His
1220			123	0		1	240			1250)		126	0		1	270		
AAC	CGC Arg	GA/ Glu	Ser 410	Tyt	Het	GTT Val	CCT	TTT Phe	ATA Ile	CCA Pro	Lau	TAC Tyt	AGA Arg 420	Ass	GG7	GAT Asp	TTC Phe	TTT	ATT
1280			129	0		. 1	300			1310			132	0	•	1	330		
TCA Ser	TCC	Lys	GAT Amp 430	Lau	GGC Gly	TAT Tyr	GAC Asp	TAT Tyr	AGC Ser	TAT Tyr	CTA Leu	CAA Gln	GAT Asp 440	Ser	GAC Asp	CCA Pro	GAC Aap	TCT Ser	TTT Phe
1340			1,35	0		1	360		1	370			138	0		1	390		
CAA Gln	GAC As p	TAC	ATT Ile 450	AAG Lys	TCC	TAT Tyr	TTG Læu	GAA Glu	CAA Gln	GCG Ala	AGT Ser	CGG Arg	ATC 11e 460	TGG Trp	TCA Ser	TGG Trp	CTC Leu	CTT Leu	GGG Gly
1400			1416)		14	20		1	430			1440)		14	50		
GCG Ala	GCG Ala	ATG Het	GTA Val 470	GGG Gly	GCC Ala	GTC Val	CTC Leu	ACT Thr	GCC Ala	CTG Leu	CTG Leu	GCA Ala	GGG Gly 480	CCT Pro	GTG Val	AGC Ser	TTG Leu	CTG Leu	TGT Cys '
1460			1470)		14	80		1	490			1500)		15	10		
CGT	CAC H1s	AAG Lys	AGA Arg 490	AAG Lys	CAG Gln	CTT Leu	CCT Pro	GAA (Glu (GAA Glu	AAG Lys	CAG Gln	CCA Pro	CTC Leu 500	CTC Leu	ATG Met	GAG Glu	AAA Lys	GAA Glu	GGA Gly
1520			1530			15	40		. 1	550			1560			15	70		
TTA (

FIG 6c SUBSTITUTE SHEET

. 1620 AGC CCT GAC CTC ACT CTA ACT CAA AGT AAT GTC CAG GTT CCA GAG AAT ATC TGC TGG TAT Ser Pro Asp Leu Thr Leu Thr Gin Ser Asn Val Gin Val Pro Glu Asn Ile Cys Trp Try TIT CTG TAA AGA CCA TIT GCA AAA TIG TAA CCT AAT ACA AAG TGT AGC CTT CTT CCA ACT Phe Leu ----CAG GTA GAA CAC ACC TGT CTT TGT CTT GCT GTT TTC ACT CAG CCC TTT TAA CAT TTT CGC 1770 . . CTA AGC CCA TAT GTC TAA GGA AAG GAT GCT ATT TGG TAA TGA GGA ACT GTT ATT TGT ATG TGA ATT AAA AGT GCT CTT AGG AAT TC

> FIG 60 SUBSTITUTE SHEET

,		memational Application No	T/US87/02561
	SIFICATION OF SUBJECT MATTER (if several class		
IPC(4	g to International Patent Classification (IPC) or to both N): C07H 15/12; C12Q 1/68; C1 : 536/27; 435/6, 70, 108, 172	2P 21/02; See Attac	chment
	S SEARCHED		
	Minimum Docum	nentation Searched 4	
Classificat	ion System :	Classification Symbols	
υ.	s. 536/27; 435/6,70,108	,172.3,189,320	
•		r than Minimum Documentation ats are Included in the Fields Searched 5	
III. DOCL	JMENTS CONSIDERED TO BE RELEVANT 14		•
Category *		opropriate, of the relevant passages 17	Relevant to Claim No. 13
Y	NUCLEIC ACIDS RESEARCH Volume 14, issued 25 Ma (SHIBAHARA ET AL), "Clo expression of cDNA mous See pages 2413-2427.	(Oxford), rch 1986 ning and	1-9
Y	CHEMICAL ABSTRACTS (Col USA), Volume 100, No. 5 30 January 1984 (SEKIGU "Pleiotrophic cytoplasm of gene expression in m reconstituted cells (nu transplanted cells).", 295, column 2, the abst 32667x, JINRUI IDENGAKU 1983, 28(2), 82-92 (Jap	, issued CHI) ic control ammalian clear see page ract No. ZASSHI,	1-7,9-12
Y	JOURNAL OF BIOLOGICAL C (Baltimore, Maryland, U Volume 258, issued 25 D (GAULTON ET AL), "Contr gene expression and its neural crest induction See pages 14845-14849.	SA), ecember 1983 ol of tryosinase relationship to	1-12
• Sacrici	categories of cited documents: 15	"T" later document sublished steet	the international filips data
"A" docucons "E" earlie filing "L" docuwhic citati "O" docuothe	categories of cited documents: 15 Iment defining the general state of the art which is not idered to be of particular relevance er document but published on or after the international g date Iment which may throw doubts on priority claim(s) or h is cited to establish the publication date of another ion or other special reason (as specified) Iment referring to an oral disclosure, use, exhibition or r means Iment published prior to the international filing date but than the priority date claimed	"T" later document published after or priority date and not in conficited to understand the principle invention "X" document of particular relevant cannot be considered novel or involve an inventive step "Y" document of particular relevant cannot be considered to involve document is combined with one ments, such combination being in the art. "4" document member of the same	ict with the application but le or theory underlying the loc; the claimed invention cannot be considered to loc; the claimed invention an inventive step when the or more other such docuobvious to a person skilled
IV. CERTI			
	Actual Completion of the International Search ²	Date of Mailing of this International Se	earch Report ¹
	31 December 1987	Signature of Authorized Officer 10	
нивтлацопа		Jan Ahr	_
	_ISA/US	Thomas D. Mays	

PCT/US87/02561

Attachment To Form PCT/ISA/210, Part I.

IPC(4): C12Q 1/26; C12P 13/22; C12N 15/00; C12N 7/00

_

3

	ENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHI Citation of Document, 19 with indication, where appropriate, of the relevant passages 17	Relevant to Claim No 13
Calegory	Chandle of Document, while included in the appropriate to the parents	1
Y	CHEMICAL ABSTRACTS (Columbus, Ohio, USA), Volume 81, No. 5, issued 5 August 1974 (PAWELEK ET AL) "Genetic control of melanization. Isolation and analysis of amelanotic	1-12
	variants from cultured melanoma cells",	ı
	see page 271, column 2, the abstract	1
•	No. 23599p, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, 1974, 71(4), 1073-1077 (Eng).	
Y .	CHEMICAL ABSTRACTS (Columbus, Ohio, Volume 72, No. 13, issued 30 March 1970 (OTTOLENGHI-NIGHTINGALE) "Induction of melanin synthesis in albino mouse skin by DNA from pigmented mice", see page 162, column 1, the abstract No. 64375v, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, 1969, 64(1), 184-189 (Eng).	7-12

	FORMATION C						-	
	-							
	_							
*								
							İ	
	·							
						-	ŀ	
:.								
:	•				-			-
i .								
i						÷		
i					-			-
							-	
OBSERV	ATIONS WHE	RE CERTA	IN CLAIMS V	VERE FOUND	UNSEARCH	ARIEIO		
								
s internation:	il search report i	nas not been	established in	respect of certa	in claims unde	r Article 17(2)	(a) for the follow	ing reasons:
Claim num							s Authority, nan	
								, .
	•							
			_					
	-							
					-			
Claim num ments to s	bers , bec uch an extent tha	ause they re at no meanin	late to parts of	the internation	al application i	hat do not con	nply with the pre	scribed require-
			•			, specifically,		
				•				,
								÷
								-
				-				
				-				
			OF INVENTE					
OBSERV	ATIONS WHE	RE UNITY	AL IMARM LIN	ON IS LACKI	NG II			
		RE UNITY						
	ATIONS WHE	RE UNITY				ation as follow	's:	
		RE UNITY				ation as follow	s:	
Internationa	Searching Auti					ation as follow	s:	
Internationa						ation as follow	·s:	-
Internationa	Searching Auti					ation as follow	'S:	
Internationa	Searching Auti					ation as follow	'S:	
International See A	Searching Auti	earch fees we	multiple inventi	ons in this inter	national applic			rchahle claime
International See A	Searching Auti	earch fees we	multiple inventi	ons in this inter	national applic			rchable claims
International See A As all requi	I Searching Auti	earch fees we	multiple inventions and the search fees we	ons in this inter	national applications this internation	nai search repo	ort covers all sea	
International See A As all required the international	Searching Auti	earch fees we	multiple inventions and the search fees we	ons in this inter	national applications this internation	nai search repo	ort covers all sea	
International See A As all required the international	I Searching Auti	earch fees we	multiple inventions and the search fees we	ons in this inter	national applications this internation	nai search repo	ort covers all sea	
International See A As all required the international	I Searching Auti	earch fees we	multiple inventions and the search fees we	ons in this inter	national applications this internation	nai search repo	ort covers all sea	
As all required the international As only sorthose claim	I Searching Auth	earch fees wer on. ed additional onal applicat	multiple inventions and by timely paid by timely paid by timely paid by t	ons in this inter	national applicantial this internation by the applicant pecifically claim pecificall	nal search repo t, this internati ms:	ort covers all sea onal search repu	oft covers only
As all required the international As only sorthose claim	I Searching Auti	earch fees wer on. ed additional onal applicat	multiple inventions and by timely paid by timely paid by timely paid by t	ons in this inter	national applicantial this internation by the applicant pecifically claim pecificall	nal search repo t, this internati ms:	ort covers all sea onal search repu	oft covers only
As all required the international As only sorthose claim	I Searching Auth	earch fees were the fees were the fees were the claim	multiple inventions and by timely paid by timely paid by timely paid by t	ons in this inter	national applicantial this internation by the applicant pecifically claim pecificall	nal search repo t, this internati ms:	ort covers all sea onal search repu	oft covers only
As all required the international As only sorthose claim	I Searching Auth	earch fees wer on. ed additional onal applicat	multiple inventions and by timely paid by timely paid by timely paid by t	ons in this inter	national applicantial this internation by the applicant pecifically claim pecificall	nal search repo t, this internati ms:	ort covers all sea onal search repu	oft covers only
As all required the invention	I Searching Autional Searching Autional applications of the requires of the international search first mentioned	earch fees were a finished additional applications on the claim the claim 1-6	multiple inventions of timely paid by timely paid by timely paid by the series of the	ons in this inter by the applicant, are timely paid be ees were paid, s the applicant. Co	national applicantial this internation of the applicant pecifically claim on sequently, there:	nal search repo t, this internati ms: nis internationa	ort covers all sea onal search repo al search report	ort covers only
As all required the invention	I Searching Auth	earch fees were a finished additional applications on the claim the claim 1-6	multiple inventions of timely paid by timely paid by timely paid by the series of the	ons in this inter by the applicant, are timely paid be ees were paid, s the applicant. Co	national applicantial this internation of the applicant pecifically claim on sequently, there:	nal search repo t, this internati ms: nis internationa	ort covers all sea onal search repo al search report	ort covers only
As all required the invention	I Searching Auti	earch fees were a finished additional applications on the claim the claim 1-6	multiple inventions of timely paid by timely paid by timely paid by the series of the	ons in this inter by the applicant, are timely paid be ees were paid, s the applicant. Co	national applicantial this internation of the applicant pecifically claim on sequently, there:	nal search repo t, this internati ms: nis internationa	ort covers all sea onal search repo al search report	ort covers only
As all required the invention As all search and the invention As all search and the invention As all search and the payment ark on Protest	I Searching Auti	earch fees were and in the claim 1 - 6 Id be searcheonal fees.	multiple inventions and be search fees we know for which fee timely paid by the search feed without effor ed without ed without ed without ed without ed without ed without effor ed without ed wit	ons in this inter by the applicant, ere timely paid bees were paid, s the applicant. Co	national applicantial this internation of the applicant pecifically claim on sequently, there:	nal search repo t, this internati ms: nis internationa	ort covers all sea onal search repo al search report	ort covers only

Attachment To Form PCT/ISA/210, Part VI.

- Claims 1-6 drawn to a cDNA gene from lambda mel 34 clone, bacteriophage vector, method of making tyrosinase and method of using cDNA gene as a probe for albinism; class 536 subclass 27 and class 435 subclasses 6, 108, 172.3, 189 and 320.
- II. Claim 7 drawn to a second use of said cDNA gene as a probe for melanoma; class 435 subclass 6.
- III. Claim 9 drawn to a third use of said cDNA gene as a probe for diagnosing prenatal albinism; class 435 subclass 6.
- IV. Claim 3 drawn to a fourth method of using said aDNA gene for regulation of production of human melanin; class +35 subclass 70.
- V. Claims 10-12 drawn to a second cDNA gene from lambda mel 17-1 clone, bacteriophage vector and use of said second cDNA gene as a probe for melanin biosynthesis; class 536 subclass 27 and class 435 subclass 6 and 320.